Novel sublingual wafer platform technology

Superior drug delivery

  • Increased bioavailability
  • Rapid onset of therapeutic action
  • Predictable effect
  • Convenient
  • Fixed unit dose

Patented platform technology

  • Delivers small molecules across a range of indications
  • Globally patented

Proprietary manufacturing process

  • Freeze-dried solid dosage form
  • In-house expertise
  • TGA compliant
  • GMP facility

Repurposing drugs
with WaferiX

  • are poorly absorbed when swallowed
  • can only be administered intravenously
  • require rapid onset of action
  • benefit from product life-cycle extension

Repurposed drugs have superior delivery and absorption, improved patient compliance and renewed market exclusivity.


Approved active compounds have established safety and toxicity profiles. We reposition these actives for new indications with unmet medical needs. Leveraging on expedited pathways like FDA 505(b)(2), development risks and costs are lowered with faster speed to market.

We develop innovative therapies that improve the quality of life for patients with pain, chronic diseases and debilitating conditions.

Our Product Portfolio

Pharmaceutical Products

We have a robust pipeline of CNS products that are being developed and clinically evaluated. Our portfolio includes Wafermine (sublingual ketamine) for pain and depression, BnoX (sublingual buprenorphine) for pain, and Wafesil (sublingual sildenafil) for erectile dysfunction.

Medicinal Cannabis Products

Our revolutionary sublingual cannabis wafers for medicinal and supplement use have been awarded “CBD Product of the Year 2020” by the Australian Cannabis Awards.

Nutraceutical Products

Entity, our next-generation nutraceuticals, combine unique, clinically backed formulations and superior delivery for products targeting specific conditions.


Our lead product under development is a sublingual racemic ketamine wafer which is being evaluated for the treatment of acute moderate to severe pain.

Phase 3-ready, positive results in Phase 2b

  • strong analgesic effect
  • safe and tolerable
  • non-opioid with opioid sparing effects

Strengths at every stage of the development chain

Fully integrated from R&D, manufacturing, regulatory affairs to sales.

Better Operating Efficiencies

End-to-end service, faster speed to market

Quality Control

Fully licensed, TGA-compliant cGMP facility.

Intellectual Property Protection

Proprietary freeze-drying process supported by highly trained professionals and specialised equipment.

Latest Announcements


iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2023.

More information can be found here.

iX Biopharma introduces MeltMed, a new wellness brand in the United States.

The news release can be found here.

iX Biopharma Ltd has published its FY2023 Annual Report, Sustainability Report, Notice of AGM and Proxy Form.